Zenith Flex G42785Recalls & reported problems
Cook Incorporated · Zenith Flex, AAA Main Body Extension · Class 3 · Implant
All models of Zenith Flex (54)
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 1
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 10827002427850), received between Mar 17, 2017 and Feb 26, 2021 — classified as 1 death, 1 malfunction.
The most frequently reported specific device problem is “Fluid/Blood Leak” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Most reported problems
Device problems
- Fluid/Blood Leak1
- Material Deformation1
Patient problems
- Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available1
- Death1
- Embolism/Embolus1
- Ischemia1
- No Code Available1
- No Known Impact Or Consequence To Patient1
- Paraplegia1
- Unspecified Tissue Injury1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
DeathFeb 26, 2021Fluid/Blood Leak; Fluid/Blood Leak
IT WAS REPORTED THAT A STUDY PATIENT DEVELOPED A TYPE 1B ENDOLEAK FOLLOWING IMPLANTATION OF A ZENITH AAA ENDOVASCULAR GRAFT AAA ANCILLARY COMPONENT MAIN BODY EXTENSION. ON (B)(6) 2017, A CT SCAN PERFORMED SHOWED A STABLE, TYPE IV THORACOABDOMINAL ANEURYSM WITH MILD ILIAC ANGULATION. THE PATIENT'S CELIAC, SUPERIOR-MESENTERIC (SMA), AND RIGHT RENAL ARTERIES WERE PATENT. THE LEFT RENAL ARTERY WAS NOTED TO BE OCCLUDED. NO RENAL INFARCTS WERE VIEWED. PATIENT MEASUREMENTS WERE RECORDED TO BE: MAXIMUM ANEURYSM DIAMETER: 59 MM LENGTH FROM CELIAC TO SMA: 15 MM LENGTH FROM CELIAC TO RIGHT RENAL: 40 MM LENGTH FROM CELIAC TO LEFT RENAL: 0 MM LENGTH FROM SMA TO RIGHT RENAL: 25 MM LENGTH FROM THE LOWEST RENAL ARTERY TO START OF THE ANEURYSM (MEASURED FROM DISTAL-MOST ASPECT OF RENAL ARTERY): 0 MM. ON (B)(6) 2018, THREE COOK CUSTOM-MADE DEVICES, THE COMPLAINT DEVICE, AND ONE COMPETITOR DEVICE WERE IMPLANTED WITHOUT DIFFICULTIES DURING AN ENDOVASCULAR PROCEDURE. POST-PROCEDURAL IMAGING REVEALED EVIDENCE OF A TYPE 1A ENDOLEAK, WHICH IS REPORTED UNDER MDR REF. #3002808486-2019-00778. NO DEVICE INTEGRITY ISSUES OR TECHNICAL ABNORMALITIES WERE NOTED. THE PATIENT WAS DISCHARGED ON (B)(6) 2018. ON (B)(6
Patient problems: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available; Death; Embolism/Embolus; Ischemia; No Code Available; Paraplegia; Unspecified Tissue Injury
MAUDE report 11385781 ↗MalfunctionMar 17, 2017Material Deformation; Material Deformation
ON (B)(6) 2017, A (B)(6) FEMALE PATIENT UNDERWENT A PROCEDURE FOR ENDOVASCULAR ANEURYSM REPAIR (EVAR). THIS PATIENT WAS NOT A ANATOMICALLY SUITABLE FOR THE PROCEDURE SINCE SEVERE CURVATURE WAS OBSERVED FROM THE PROXIMAL NECK TO THE ANEURYSM, HOWEVER, THE PHYSICIAN OPTED TO PERFORM THE EVAR DUE TO THE RISK ASSOCIATED WITH AN OPEN ABDOMINAL SURGERY EXACERBATED BY THE PATIENT'S AGE. AN ACCESS ROUTE LARGER THAN 7.7MM WAS MADE AND IT WAS NOTED THAT MILD CALCIFICATION EXISTED IN THE COMMON ILIAC ARTERY (CIA) AND THE EXTERNAL ILIAC ARTERY (EIA). THE PROCEDURE WAS PLANNED ACCORDING TO AN ANTICIPATED PROXIMAL TYPE I ENDOLEAK DUE TO SEVERE TORTUOSITY FROM THE PROXIMAL NECK TO THE ANEURYSM AND A BODY EXTENSION PLACEMENT WAS PLANNED AS ADDITIONAL TREATMENT IF NECESSARY. FIRST, EVAR WITH MAIN BODY, IPSILATERAL AND CONTRALATERAL ILIAC LEGS WITH BALLOON TOUCH WAS COMPLETED. ANGIOGRAPHY CONFIRMED A PROXIMAL TYPE I ENDOLEAK AS PREDICTED. THE PHYSICIAN PERFORMED BODY EXTENSION PLACEMENT AS PLANNED. A ZENITH AAA ENDOVASCULAR GRAFT AAA ANCILLARY COMPONENT MAIN BODY EXTENSION WAS SELECTED AND INSERTED INTO THE PATIENT. HOWEVER, THE PHYSICIAN ENCOUNTERED STRONG RESISTANCE AT THE PUNCTURE SITE, SO HE REM
Patient problems: No Known Impact Or Consequence To Patient
MAUDE report 6412877 ↗
Other SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT devices
- Endurant® IIs ESBF2814C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls34 deaths254 reports
- Endurant® IIs ESBF3214C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls19 deaths173 reports
- Endurant® IIs ESBF3614C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT1 recall37 deaths214 reports
- Endurant® IIs ESBF2514C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls18 deaths136 reports
- Endurant® IIs ESBF2314C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls9 deaths60 reports
- RelayPro Thoracic Stent-Graft System 28-N4-34-154-34UBolton Medical Inc. · System, Endovascular Graft, Aortic Aneurysm Treatment3 recalls7 reports
- Vela Proximal Endograft System A34-34/C100-O20 VEndologix LLC · System, Endovascular Graft, Aortic Aneurysm Treatment3 deaths152 reports
- Endurant® II ETCF2828C49EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls7 deaths44 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page